ALLEGAN, Mich., Oct. 6 /PRNewswire-FirstCall/ -- Perrigo Company
(Nasdaq: PRGO; TASE) announced today that it has acquired Laboratorios
Diba, S.A. for approximately $25 million in cash. Based in Guadalajara,
Mexico, privately-held Laboratorios Diba is a store brand manufacturer of
over-the-counter (OTC) and prescription pharmaceuticals, including
antibiotics, hormonals and opthalmics. The acquisition is expected to add
nearly $15 million of annual sales.
Perrigo's Chairman and CEO Joseph C. Papa stated, "Perrigo has been in
the Mexican market for more than 65 years and is the leading supplier of
prescription and OTC store brand products there. The acquisition of
Laboratorios Diba will enable us to market an additional 150 formulas and
50 trademarks into the rapidly growing Mexican store brand market, saving
consumers money on their healthcare options. This further exemplifies
Perrigo's commitment to meeting the growing need for quality, affordable
healthcare around the world."
Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes OTC and prescription pharmaceuticals,
nutritional products, active pharmaceutical ingredients (API) and consumer
products. The Company is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. The Company's primary
markets and locations of manufacturing facilities are the United States,
Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (
http://www.perrigo.com ).
Note: Certain statements in this press release are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended, and are subject to the safe harbor created thereby.
These statements relate to future events or the Company's future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause the actual results, levels of activity, performance
or achievements of the Company or its industry to be materially different
from those expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology such as
"may," "will," "could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "estimate," "predict," "potential" or other comparable
terminology. The Company has based these forward-looking statements on its
current expectations, assumptions, estimates and projections. While the
Company believes these expectations, assumptions, estimates and projections
are reasonable, such forward-looking statements are only predictions and
involve known and unknown risks and uncertainties, many of which are beyond
the Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year
ended June 28, 2008, as well as the Company's subsequent filings with the
Securities and Exchange Commission, may cause actual results, performance
or achievements to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless otherwise
required by applicable securities laws, the Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
SOURCE Perrigo Company
 back to top
Related links:
http://www.perrigo.com
CONTACT:
Arthur J. Shannon, Vice President, Investor
Relations and Communication, Perrigo Company, +1-269-686-1709,
ajshannon@perrigo.com
|
